Sort   by:  
 Page size 
TranscriptomicsTranscription profiling by array of mouse osteocyte MLO-Y4 cells treated with low doses of the nitrogen-containing bisphosphonates alendronate and risedronate
Differential Gene expression analysis was conducted in order to study the effect of low doses of Alendronate and Risedronate on osteocyte MLO-Y4 cells. Alendronate and Risedronate are Nitrogen-containing Bisphosphonates (N-BPs), compounds used to treat excessive bone resorption, and low doses of N-B...
ORGANISM(S): Mus musculus 
2009-02-15 | E-MEXP-1470 | biostudies-arrayexpress
ProteomicsAlendronate and Osteonecrosis of the Jaw
Objectives: Osteonecrosis of the jaw (ONJ), a necrotic bone disease unique to the craniofacial region, is often observed among cancer patients treated with bisphosphonate (BP)-based chemotherapy and becomes a costly and debilitating source of pain and reduced quality of life. Elucidation of clinicop...
ORGANISM(S): Homo sapiens (Human) 
2021-09-10 | PXD024585 | Pride
Ripk3 Osteonecrosis Alendronate Proteomics Wnt/gsk3/b-catenin 
TranscriptomicsExpression profile of osteoclasts treated with bisphosphonates
Bisphosphonates are the mainstay of therapy worldwide for osteoporosis. They inhibit the activities of the osteoclasts, the bone resorption cells. While bisphosphonates are known to block farnesyl pyrophsophate synthase to exert their anti-resorptive action, the detailed mechanism is not well unde...
ORGANISM(S): Homo sapiens 
2014-11-06 | E-GEOD-63009 | biostudies-arrayexpress
GenomicsAsthmaNet Proof of Concept Study of Alendronate for Asthma (ALFA_BioLINCC)
AsthmaNet Proof of Concept Study of Alendronate for Asthma (ALFA_BioLINCC)
PRJNA1431496 | ENA
GenomicsAsthmaNet Proof of Concept Study of Alendronate for Asthma (ALFA_BioLINCC)
AsthmaNet Proof of Concept Study of Alendronate for Asthma (ALFA_BioLINCC)
PRJNA1431497 | ENA
GenomicsEffect of Alendronate on Survival and Bone Properties in Nothobranchius furzeri: Insights from a Model of Accelerated Aging
Effect of Alendronate on Survival and Bone Properties in Nothobranchius furzeri: Insights from a Model of Accelerated Aging
PRJNA1381684 | ENA
TranscriptomicsEffect of Alendronate on Survival and Bone Properties in Nothobranchius furzeri: Insights from a Model of Accelerated Aging
Alendronate, a nitrogen containing bisphosphonate, effectively inhibits osteoclastic bone resorption and is considered as first line treatment of osteoporosis and Paget´s disease. Additionally, several studies suggest a beneficial effect on mortality that goes beyond life-extending effects attribute...
ORGANISM(S): Nothobranchius furzeri 
2026-06-01 | GSE313857 | GEO
UnknownCost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.
Not available
S-EPMC8053143 | biostudies-literature
UnknownBone Mineral Density After Transitioning From Denosumab to Alendronate.
Not available
S-EPMC7112973 | biostudies-literature
UnknownCost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide.
Not available
S-EPMC6874180 | biostudies-literature
Sort   by:  
 Page size